Clinical Trials
13 trialsNCT05956041 2026-05-05
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT05996185 2026-04-14
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University
Phase 2 Recruiting
NCT07529405 2026-04-14
CurbMF
Virogen Biotechnology Inc.
Phase 2 Not yet recruiting
NCT06698003 2026-03-05
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04930653 2025-10-14
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT04256018 2025-07-02
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Stanford University
Phase 2 Recruiting
NCT01611142 2024-06-17
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT01226472 2024-04-25
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT01626664 2024-04-25
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT04745234 2024-04-25
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Kyowa Kirin Co., Ltd.
Phase 2 Unknown
NCT04128072 2024-04-05
MOGAT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT01173887 2017-03-30
Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00920790 2017-03-29
Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
Kyowa Kirin Co., Ltd.
Phase 2 Completed